Risk-Based First-Line Selection in Advanced Renal Cell Carcinoma

In this introductory segment on advanced renal cell carcinoma, Dr. Wulff frames the challenge of selecting among multiple NCCN category 1 first-line regimens, including IO-IO and IO-TKI combinations. Dr. McGregor and Dr. Geynisman discuss how they approach treatment selection in clinical practice when several evidence-based options exist. The conversation highlights that while both rely on guideline recommendations, their decision making is driven by key clinical factors such as disease burden, need for rapid response, and patient-specific considerations. IO-TKI combinations are often favored in patients requiring early disease control, whereas IO-IO approaches may be considered in appropriate patients where durability of response is a priority. The panel also reflects on how differences in clinical experience and interpretation of trial data can lead to variation in practice, reinforcing that treatment selection in advanced renal cell carcinoma remains highly individualized despite a well-defined guideline framework.